Genmab
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Genmab and other ETFs, options, and stocks.About GMAB
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
CEOJan G. J. van de Winkel
CEOJan G. J. van de Winkel
Employees2,682
Employees2,682
HeadquartersCopenhagen, Central Denmark
HeadquartersCopenhagen, Central Denmark
Founded1998
Founded1998
Employees2,682
Employees2,682
GMAB Key Statistics
Market cap18.37B
Market cap18.37B
Price-Earnings ratio18.85
Price-Earnings ratio18.85
Dividend yield—
Dividend yield—
Average volume1.81M
Average volume1.81M
High today$29.49
High today$29.49
Low today$28.70
Low today$28.70
Open price$29.06
Open price$29.06
Volume2.09M
Volume2.09M
52 Week high$35.43
52 Week high$35.43
52 Week low$17.24
52 Week low$17.24
GMAB News
TipRanks 3d
Genmab Expands Oncology Pipeline With New First-in-Human GEN1079 TrialGenmab (Otc) (GMAB) announced an update on their ongoing clinical study. Genmab (GMAB) has launched a first-in-human Phase 1 trial titled “First-in-human, Open...
Analyst ratings
69%
of 26 ratingsBuy
69.2%
Hold
30.8%
Sell
0%
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.